REDWOOD CITY, Calif.,
Feb. 20, 2015 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that Timothy E. Morris, chief financial
officer will be presenting at RBC Capital Markets' Global
Healthcare Conference and Cowen and Company's 35th Annual
Healthcare Conference. Details of the two presentations are
as follows:
RBC Capital Markets' Global Healthcare
Conference
Date: Tuesday February
24th
Location: The New York Palace Hotel
Presentation Time: 11:30am ET,
8:30am PT
Cowen and Company 35th Annual Healthcare
Conference
Date: Monday March
2nd
Location: The Boston Marriott Copley Place
Presentation Time: 1:30 pm ET,
10:30am PT
Presentations will be webcast live and can be accessed through
the Investors page at www.acelrx.com. For those not available
to listen to the live broadcast, a replay will be archived for 90
days and available through the Investors page on
www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, Zalviso, is designed
to improve the management of moderate-to-severe acute pain in adult
patients in the hospital setting by utilizing a high therapeutic
index opioid, through a non-invasive delivery route via a
pre-programmed, patient-controlled analgesia device. AcelRx has
announced positive results from each of the three completed Phase 3
clinical trials for Zalviso, and has submitted an NDA to the FDA
seeking approval for Zalviso in the treatment of moderate-to-severe
acute pain in adult patients in the hospital setting and on
July 25th, 2014 received a
Complete Response Letter from the FDA. AcelRx plans to initiate a
Phase 3 clinical trial for ARX-04, a product candidate for the
treatment of moderate-to-severe acute pain in a medically
supervised setting. The Company has two additional pain treatment
product candidates, ARX-02 and ARX-03, which have completed Phase 2
clinical development. For additional information about AcelRx's
clinical programs, please visit www.acelrx.com.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-participate-at-two-upcoming-investor-events-300038898.html
SOURCE AcelRx Pharmaceuticals, Inc.